ClinicalTrials.gg
CompletedNCT06619314Updated Feb 11, 2026

A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)

A Phase 1 interventional study of Calderasib and PPI in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2023, 2 years 11 months ago, and no results have been posted to the registry.
  • Registered 1 year after the study started (first participant enrolled Sep 2023, registered Sep 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of food, formulation, and a PPI on the levels of calderasib in a person's body over time.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing.
  • Medically healthy with no medical history.

Exclusion criteria

Exclusion Criteria:

  • Has a history of cancer.
  • Has had major surgery and/or donated or lost significant volume of blood.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Calderasib Treatment A

    Participants will receive calderasib on Day 1 on an empty stomach

    Drug: Calderasib

  • Experimental
    Calderasib Treatment B

    Participants will receive calderasib on Day 1 after a high-fat/high-calorie breakfast

    Drug: Calderasib

  • Experimental
    Calderasib Treatment C

    Participants will receive calderasib Formulation 1 on Day 1

    Drug: Calderasib

  • Experimental
    Calderasib Treatment D

    Participants will receive calderasib Formulation 2 on Day 1

    Drug: Calderasib

  • Experimental
    Calderasib Treatment E

    Participants will receive calderasib without a PPI on Day 1

    Drug: Calderasib

  • Experimental
    Calderasib Treatment F

    Participants will receive calderasib with a PPI on Day 5

    Drug: Calderasib · Drug: PPI

Interventions

  • Oral Tablet

    Also known as: MK-1084

  • DrugPPI

    Oral Capsule

06

What researchers measure

Primary outcomes

  1. Food effect: Area Under the Concentration-Time Curve from 0 to Infinity (AUC0-inf) of Calderasib

    Blood samples will be collected to determine the AUC0-inf of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  2. Food Effect: Maximum Plasma Concentration (Cmax) of Calderasib

    Blood samples will be collected to determine the Cmax of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  3. Formulation Effect: Area Under the Concentration-Time Curve from 0 to the Time of the Last Quantifiable Sample (AUC0-last) of Calderasib

    Blood samples will be collected to determine the AUC0-last of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  4. Formulation Effect: AUC0-inf of Calderasib

    Blood samples will be collected to determine the AUC0-inf of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  5. Formulation Effect: Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of Calderasib

    Blood samples will be collected to determine the AUC0-24 of calderasib.

    Time frame: At designated timepoints (up to 24 hours postdose)

  6. Formulation Effect: Cmax of Calderasib

    Blood samples will be collected to determine the Cmax of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  7. Formulation Effect: Plasma Concentration at 24 hours (C24) of Calderasib

    Blood samples will be collected to determine the C24 of calderasib.

    Time frame: 24 hours postdose

  8. Formulation Effect: Lag Time (tlag) of Calderasib

    Blood samples will be collected to determine the tlag of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  9. Formulation Effect: Time to Maximum Plasma Concentration (Tmax) of Calderasib

    Blood samples will be collected to determine the Tmax of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  10. Formulation Effect: Apparent Terminal Half-Life (t1/2) of Calderasib

    Blood samples will be collected to determine the t1/2 of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  11. Formulation Effect: Apparent Clearance (CL/F) of Calderasib

    Blood samples will be collected to determine the CL/F of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  12. Formulation Effect: Apparent Volume of Distribution During Terminal Phase (Vz/F) of Calderasib

    Blood samples will be collected to determine the Vz/F of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  13. Proton Pump Inhibitor (PPI) Effect: AUC0-inf of Calderasib

    Blood samples will be collected to determine the AUC0-inf of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  14. PPI Effect: Cmax of Calderasib

    Blood samples will be collected to determine the Cmax of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

Secondary outcomes

  1. Food Effect: AUC0-last of Calderasib

    Blood samples will be collected to determine the AUC0-last of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  2. Food Effect: AUC0-24 of Calderasib

    Blood samples will be collected to determine the AUC0-24 of calderasib.

    Time frame: At designated timepoints (up to 24 hours postdose)

  3. Food Effect: C24 of Calderasib

    Blood samples will be collected to determine the C24 of calderasib.

    Time frame: 24 hours postdose

  4. Food Effect: tlag of Calderasib

    Blood samples will be collected to determine the tlag of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  5. Food Effect: Tmax of Calderasib

    Blood samples will be collected to determine the Tmax of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  6. Food Effect: t1/2 of Calderasib

    Blood samples will be collected to determine the t1/2 of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  7. Food Effect: CL/F of Calderasib

    Blood samples will be collected to determine the CL/F of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  8. Food Effect: Vz/F of Calderasib

    Blood samples will be collected to determine the Vz/F of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  9. Food Effect: Number of Participants Who Experience a Treatment Emergent Adverse Event (TEAE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 2 months

  10. Food Effect: Number of Participants Who Discontinue Study Treatment Due to a TEAE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 2 months

  11. Formulation Effect: Number of Participants Who Experience a TEAE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 2 months

  12. Formulation Effect: Number of Participants Who Discontinue Study Treatment Due to a TEAE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 2 months

  13. PPI Effect: AUC0-last of Calderasib

    Blood samples will be collected to determine the AUC0-last of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  14. PPI Effect: AUC0-24 of Calderasib

    Blood samples will be collected to determine the AUC0-24 of calderasib.

    Time frame: At designated timepoints (up to 24 hours postdose)

  15. PPI Effect: C24 of Calderasib

    Blood samples will be collected to determine the C24 of calderasib.

    Time frame: 24 hours postdose

  16. PPI Effect: tlag of Calderasib

    Blood samples will be collected to determine the tlag of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  17. PPI Effect: Tmax of Calderasib

    Blood samples will be collected to determine the Tmax of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  18. PPI Effect: t1/2 of Calderasib

    Blood samples will be collected to determine the t1/2 of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  19. PPI Effect: CL/F of Calderasib

    Blood samples will be collected to determine the CL/F of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  20. PPI Effect: Vz/F of Calderasib

    Blood samples will be collected to determine the Vz/F of calderasib.

    Time frame: At designated timepoints (up to 48 hours postdose)

  21. PPI Effect: Number of Participants Who Experience a TEAE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 2 months

  22. PPI Effect: Number of Participants Who Discontinue Study Treatment Due to a TEAE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 2 months

07

Study locations

1 site
  • Celerion (Site 0001)
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Nov 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2024
First posted
Oct 1, 2024
StartActual
Sep 20, 2023
Primary completionActual
Nov 25, 2023
CompletionActual
Nov 25, 2023
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06619314
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Sep 20, 2023
Primary completion
Nov 25, 2023
Completion
Nov 25, 2023
Last update
Feb 11, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Calderasib

Start the discussion